{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:16:56Z","timestamp":1790662616568,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24DK116180"],"award-info":[{"award-number":["K24DK116180"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ekir.2021.05.020","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T05:34:53Z","timestamp":1622871293000},"page":"2261-2269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease"],"prefix":"10.1016","volume":"6","author":[{"given":"Orlando M.","family":"Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2021.05.020_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semnephrol.2006.05.009","article-title":"Iron supplementation in renal anemia","volume":"26","author":"Fishbane","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.020_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199808273390910","article-title":"Erythropoietin for end-stage renal disease","volume":"339","author":"Adamson","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.020_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"Lopez","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2021.05.020_bib5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.semnephrol.2016.05.002","article-title":"Disorders of iron metabolism and anemia in chronic kidney disease","volume":"36","author":"Panwar","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0002-9343(68)90069-7","article-title":"Body iron excretion in man: a collaborative study","volume":"45","author":"Green","year":"1968","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2021.05.020_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/713609332","article-title":"Molecular mechanisms and regulation of iron transport","volume":"40","author":"Chung","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.ekir.2021.05.020_bib9","doi-asserted-by":"crossref","first-page":"19906","DOI":"10.1074\/jbc.M000713200","article-title":"A\u00a0novel mammalian iron-regulated protein involved in intracellular iron metabolism","volume":"275","author":"Abboud","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2021.05.020_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmet.2005.01.003","article-title":"The iron exporter ferroportin\/Slc40a1 is essential for iron homeostasis","volume":"1","author":"Donovan","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2021.05.020_bib11","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1073\/pnas.0409409102","article-title":"Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin","volume":"102","author":"Knutson","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2021.05.020_bib12","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2021.05.020_bib13","first-page":"2090","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Sci Signal"},{"key":"10.1016\/j.ekir.2021.05.020_bib14","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood-2013-08-522466","article-title":"Anti-hepcidin therapy for iron-restricted anemias","volume":"122","author":"Nemeth","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2021.05.020_bib15","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2013-06-505792","article-title":"A\u00a0fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates","volume":"122","author":"Cooke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2021.05.020_bib16","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2021.05.020_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MOH.0000000000000236","article-title":"Hepcidin regulation in the anemia of inflammation","volume":"23","author":"Wang","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ekir.2021.05.020_bib18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.17252","article-title":"Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders","volume":"193","author":"Xu","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2021.05.020_bib19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2021.05.020_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.14143","article-title":"Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey","volume":"175","author":"Hohlbaum","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ekir.2021.05.020_bib21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2021.05.020_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","article-title":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","volume":"92","author":"Sugahara","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.020_bib23","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.pcl.2013.08.012","article-title":"Hematologic manifestations of systemic disease (including iron deficiency, anemia of inflammation and DIC)","volume":"60","author":"Witmer","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.ekir.2021.05.020_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1081\/CLT-200068842","article-title":"Iron ingestion: an evidence-based consensus guideline for out-of-hospital management","volume":"43","author":"Manoguerra","year":"2005","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.ekir.2021.05.020_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2021.05.020_bib26","series-title":"Encyclopedia of Dietary Supplements","first-page":"432","article-title":"Iron","author":"Murray-Kolb","year":"2015"},{"key":"10.1016\/j.ekir.2021.05.020_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9343(00)00396-X","article-title":"Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation","volume":"109","author":"Barton","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.ekir.2021.05.020_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ekir.2021.05.020_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5581\/1516-8484.20110123","article-title":"Intravenous iron therapy: how far have we come?","volume":"33","author":"Can\u00e7ado","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.ekir.2021.05.020_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14740338.2021.1853098","article-title":"Improving the safety of intravenous iron treatments for patients with chronic kidney disease","volume":"20","author":"Kassianides","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ekir.2021.05.020_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ekir.2021.05.020_bib32","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2215\/CJN.08340811","article-title":"The role of catalytic iron in acute kidney injury","volume":"6","author":"Shah","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2021.05.020_bib34","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.clinthera.2016.08.012","article-title":"A\u00a0review of ferric pyrophosphate citrate (Triferic) use in hemodialysis patients","volume":"38","author":"Albright","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.ekir.2021.05.020_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/kisup.2012.33","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Chapter 1: diagnosis and evaluation of anemia in CKD","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2021.05.020_bib36","series-title":"Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. NICE Clinical Guidelines, No. 39","year":"2006"},{"key":"10.1016\/j.ekir.2021.05.020_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib38","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.05.020_bib39","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2753.2007.00932.x","article-title":"Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice","volume":"14","author":"Bhandari","year":"2008","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.ekir.2021.05.020_bib40","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.05.020_bib41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A\u00a0randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.020_bib42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A\u00a012-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.05.020_bib43","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2215\/CJN.15291219","article-title":"Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial","volume":"15","author":"Womack","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib45","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A\u00a0pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib46","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.05.020_bib47","first-page":"CD007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"2","author":"O\u2019Lone","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2021.05.020_bib48","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(17)30182-5","article-title":"Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials","volume":"4","author":"Stoffel","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ekir.2021.05.020_bib49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.2019004330","article-title":"How I treat renal anemia","volume":"136","author":"Fishbane","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2021.05.020_bib50","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2021.05.020_bib51","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients\u2019 Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.05.020_bib54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ki.2015.203","article-title":"Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients","volume":"88","author":"Gupta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.05.020_bib55","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic\u2122) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.05.020_bib56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/089686080802800210","article-title":"Intravenous iron sucrose in peritoneal dialysis patients with renal anemia","volume":"28","author":"Li","year":"2008","journal-title":"Perit Dials Int"},{"key":"10.1016\/j.ekir.2021.05.020_bib57","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of Anemia in Incident Dialysis Patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.nephro.2011.03.010","article-title":"Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis. Article in French","volume":"7","author":"Ficheux","year":"2011","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.ekir.2021.05.020_bib59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3747\/pdi.2016.00193","article-title":"Anemia in peritoneal dialysis patients; iron repletion, current and future therapies","volume":"37","author":"Zeidan","year":"2017","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.ekir.2021.05.020_bib60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1681\/ASN.V94664","article-title":"Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study","volume":"9","author":"Ahsan","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib61","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/ndt\/16.9.1879","article-title":"A\u00a0prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients","volume":"16","author":"Johnson","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.05.020_bib62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2215\/CJN.01541005","article-title":"Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial","volume":"1","author":"Singh","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib63","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000366482","article-title":"JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis","volume":"128","author":"Yokoyama","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2021.05.020_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CNP71125","article-title":"Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients","volume":"71","author":"Grimmelt","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2021.05.020_bib66","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/TP.0b013e318248375a","article-title":"A\u00a0randomized controlled trial of intravenous or oral iron for posttransplant anemia in kidney transplantation","volume":"93","author":"Mudge","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2021.05.020_bib67","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1399-0012.2012.01602.x","article-title":"Intravenous iron supplementation after kidney transplantation","volume":"26","author":"Rozen-Zvi","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ekir.2021.05.020_bib68","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ejhf.236","article-title":"Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?","volume":"17","author":"McDonagh","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2021.05.020_bib69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.amjcard.2018.04.062","article-title":"Usefulness of oral ferric citrate in patients with iron-deficiency anemia and chronic kidney disease with or without heart failure","volume":"122","author":"McCullough","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ekir.2021.05.020_bib70","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/antiox8100498","article-title":"Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease","volume":"8","author":"Nuhu","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ekir.2021.05.020_bib71","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL Trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921012031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921012031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:38:56Z","timestamp":1762832336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024921012031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2468024921012031"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2021.05.020","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}